X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA IPCA LABS ELDER PHARMA/
IPCA LABS
 
P/E (TTM) x -0.2 39.5 - View Chart
P/BV x 0.1 3.0 3.3% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ELDER PHARMA   IPCA LABS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
IPCA LABS
Mar-17
ELDER PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs380643 59.1%   
Low Rs188503 37.4%   
Sales per share (Unadj.) Rs491.2254.4 193.1%  
Earnings per share (Unadj.) Rs-3.216.1 -19.8%  
Cash flow per share (Unadj.) Rs14.429.8 48.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs376.5194.6 193.5%  
Shares outstanding (eoy) m20.54126.20 16.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.62.3 25.7%   
Avg P/E ratio x-89.335.7 -250.4%  
P/CF ratio (eoy) x19.719.2 102.4%  
Price / Book Value ratio x0.82.9 25.6%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m5,83372,300 8.1%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,1796,960 31.3%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m10,08932,106 31.4%  
Other income Rs m257226 113.7%   
Total revenues Rs m10,34632,332 32.0%   
Gross profit Rs m-7924,448 -17.8%  
Depreciation Rs m3611,730 20.9%   
Interest Rs m2,756241 1,144.6%   
Profit before tax Rs m-3,6532,703 -135.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125675 18.5%   
Profit after tax Rs m-652,028 -3.2%  
Gross profit margin %-7.813.9 -56.7%  
Effective tax rate %-3.425.0 -13.7%   
Net profit margin %-0.66.3 -10.3%  
BALANCE SHEET DATA
Current assets Rs m9,24017,340 53.3%   
Current liabilities Rs m9,9989,559 104.6%   
Net working cap to sales %-7.524.2 -31.0%  
Current ratio x0.91.8 51.0%  
Inventory Days Days46100 46.2%  
Debtors Days Days6057 105.4%  
Net fixed assets Rs m10,12420,779 48.7%   
Share capital Rs m206252 81.5%   
"Free" reserves Rs m5,58224,499 22.8%   
Net worth Rs m7,73424,553 31.5%   
Long term debt Rs m4,8893,517 139.0%   
Total assets Rs m22,88239,595 57.8%  
Interest coverage x-0.312.2 -2.7%   
Debt to equity ratio x0.60.1 441.3%  
Sales to assets ratio x0.40.8 54.4%   
Return on assets %11.85.7 205.2%  
Return on equity %-0.88.3 -10.2%  
Return on capital %22.310.5 212.7%  
Exports to sales %3.048.6 6.2%   
Imports to sales %0.414.2 3.0%   
Exports (fob) Rs m30715,617 2.0%   
Imports (cif) Rs m434,571 0.9%   
Fx inflow Rs m30715,617 2.0%   
Fx outflow Rs m1255,828 2.2%   
Net fx Rs m1819,790 1.9%   
CASH FLOW
From Operations Rs m11,7542,764 425.2%  
From Investments Rs m-561-1,432 39.1%  
From Financial Activity Rs m-6,762-1,591 424.9%  
Net Cashflow Rs m4,432-259 -1,712.4%  

Share Holding

Indian Promoters % 39.6 45.9 86.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 16.8 25.3 66.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.4 207.5%  
Shareholders   16,479 36,892 44.7%  
Pledged promoter(s) holding % 77.6 2.1 3,624.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; IT Stocks Top Gainers(01:30 pm)

After opening the day marginally higher, share markets in India continued the momentum and are presently trading in green. Sectoral indices are trading on a mixed note, with stocks in the IT sector.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS